MCID: INF023
MIFTS: 54

Inflammatory Breast Carcinoma

Categories: Rare diseases, Cancer diseases, Reproductive diseases, Genetic diseases

Aliases & Classifications for Inflammatory Breast Carcinoma

MalaCards integrated aliases for Inflammatory Breast Carcinoma:

Name: Inflammatory Breast Carcinoma 12 14 69
Inflammatory Breast Cancer 72 49 51
Inflammatory Carcinoma of Breast 12
Inflammatory Breast Neoplasms 41
Breast Cancer, Inflammatory 49
Mastitis Carcinomatosa 12

Classifications:



External Ids:

Disease Ontology 12 DOID:6263
MeSH 41 D058922
NCIt 46 C4001
SNOMED-CT 64 254840009
UMLS 69 C0278601

Summaries for Inflammatory Breast Carcinoma

NIH Rare Diseases : 49 Inflammatory breast cancer (IBC) is a rare and aggressive type of breast cancer in which the cancer cells block the lymph vessels in the skin of the breast. This type of breast cancer is called “inflammatory” because the breast often looks swollen and red, or “inflamed.” The skin may also look dimpled like the skin of an orange. IBC can be difficult to diagnose because there is no lump to feel or detect on a mammogram. It is crucial to identify IBC right away because early diagnosis and treatment can greatly improve the outcome. Patients are often given a combination of treatments, including chemotherapy, surgery, and radiation therapy. Approximately one-third of individuals diagnosed with IBC will become long-term survivors. Like other types of breast cancer, IBC can occur in men, but usually at an older age than in women. Some studies have shown an association between family history of breast cancer and IBC, but more studies are needed to draw firm conclusions. Last updated: 9/24/2015

MalaCards based summary : Inflammatory Breast Carcinoma, also known as inflammatory breast cancer, is related to adenocarcinoma and breast cystic hypersecretory carcinoma, and has symptoms including peau d'orange, pain and edema. An important gene associated with Inflammatory Breast Carcinoma is CDH1 (Cadherin 1), and among its related pathways/superpathways are Pathways in cancer and Gastric cancer. The drugs Doxorubicin and Progesterone have been mentioned in the context of this disorder. Affiliated tissues include breast, skin and prostate, and related phenotypes are Decreased viability in esophageal squamous lineage and Decreased viability with paclitaxel

Wikipedia : 72 Inflammatory breast cancer is one of the most aggressive types of breast cancer that can occur in women... more...

Related Diseases for Inflammatory Breast Carcinoma

Diseases in the Breast Cancer family:

Breast Benign Neoplasm Inflammatory Breast Carcinoma
Sporadic Breast Cancer Breast Carcinoma in Situ

Diseases related to Inflammatory Breast Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 147)
# Related Disease Score Top Affiliating Genes
1 adenocarcinoma 29.0 CDH1 EGFR ERBB2
2 breast cystic hypersecretory carcinoma 10.2 CDH1 ERBB2
3 comedo carcinoma 10.2 ERBB2 ESR1
4 lymphangioma 10.1 EGFR PROX1
5 breast intraductal proliferative lesion 10.1 EGFR ERBB2
6 tumor suppressor gene on chromosome 11 10.1 EGFR ERBB2
7 vulvar syringoma 10.1 ESR1 PGR
8 vestibular gland benign neoplasm 10.0 ESR1 PGR
9 lung leiomyoma 10.0 ESR1 PGR
10 bartholin's gland adenoma 10.0 ESR1 PGR
11 vulvar benign neoplasm 10.0 ESR1 PGR
12 trigonitis 10.0 ESR1 PGR
13 vulvar leiomyoma 10.0 ESR1 PGR
14 predominantly cortical thymoma 10.0 ESR1 PGR
15 progesterone resistance 10.0 ESR1 PGR
16 cribriform carcinoma 10.0 ESR1 PGR
17 bartholin's gland benign neoplasm 10.0 ESR1 PGR
18 endometrial squamous cell carcinoma 10.0 ESR1 PGR
19 endometrial mucinous adenocarcinoma 10.0 ESR1 PGR
20 adenoid basal cell carcinoma 10.0 ESR1 PGR
21 deep angioma 10.0 ESR1 PGR
22 gender identity disorder 10.0 ESR1 PGR
23 cervical carcinosarcoma 10.0 ESR1 PGR
24 synchronous bilateral breast carcinoma 10.0 ESR1 PGR
25 intramuscular hemangioma 10.0 ESR1 PGR
26 estrogen excess 10.0 ESR1 PGR
27 acneiform dermatitis 10.0 EGFR ERBB2
28 glycogen-rich clear cell breast carcinoma 10.0 ESR1 PGR
29 mammographic density 10.0 ESR1 PGR
30 retinitis pigmentosa 47 10.0 ESR1 PGR
31 adenomyosis 10.0 ESR1 PGR
32 adenosquamous cell lung carcinoma 10.0 EGFR ERBB2
33 retinitis pigmentosa 20 10.0 ESR1 PGR
34 lobular neoplasia 10.0 CDH1 ERBB2 ESR1
35 adenosarcoma 10.0 ESR1 PGR
36 cervical clear cell adenocarcinoma 10.0 ESR1 PGR
37 endometriosis of ovary 10.0 ESR1 PGR
38 reproductive organ benign neoplasm 9.9 ESR1 PGR
39 pharynx cancer 9.9 CDH1 EGFR
40 uterine benign neoplasm 9.9 ESR1 PGR
41 lymphoma 9.9
42 mastitis 9.9
43 smooth muscle tumor 9.9 ESR1 PGR
44 gallbladder adenocarcinoma 9.9 EGFR ERBB2
45 pancreatic mucinous cystadenoma 9.9 ESR1 PGR
46 endometritis 9.9 ESR1 PGR
47 small intestinal adenocarcinoma 9.9 EGFR ERBB2
48 erysipeloid 9.9
49 scirrhous adenocarcinoma 9.9 ERBB2 PGR
50 breast apocrine carcinoma 9.9 ERBB2 PGR

Graphical network of the top 20 diseases related to Inflammatory Breast Carcinoma:



Diseases related to Inflammatory Breast Carcinoma

Symptoms & Phenotypes for Inflammatory Breast Carcinoma

UMLS symptoms related to Inflammatory Breast Carcinoma:


peau d'orange, pain, edema

GenomeRNAi Phenotypes related to Inflammatory Breast Carcinoma according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability in esophageal squamous lineage GR00235-A 9.43 CDH1 ERBB2 ESR1 FUT3 PGR PROX1
2 Decreased viability with paclitaxel GR00179-A-1 8.8 EGFR ERBB2
3 Decreased viability with paclitaxel GR00179-A-3 8.8 EGFR

MGI Mouse Phenotypes related to Inflammatory Breast Carcinoma:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.91 CDH1 EGFR ERBB2 ESR1 PGR PROX1
2 endocrine/exocrine gland MP:0005379 9.87 CDH1 EGFR ERBB2 ESR1 PGR PROX1
3 digestive/alimentary MP:0005381 9.8 CDH1 EGFR ERBB2 ESR1 PROX1
4 embryo MP:0005380 9.77 CDH1 EGFR ERBB2 ESR1 PGR
5 integument MP:0010771 9.73 CDH1 EGFR ERBB2 ESR1 PGR WISP3
6 muscle MP:0005369 9.55 EGFR ERBB2 ESR1 PGR PROX1
7 neoplasm MP:0002006 9.43 CDH1 EGFR ERBB2 ESR1 PGR WISP3
8 normal MP:0002873 9.17 CDH1 EGFR ERBB2 ESR1 PGR PROX1

Drugs & Therapeutics for Inflammatory Breast Carcinoma

Drugs for Inflammatory Breast Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 160)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
2
Progesterone Approved, Vet_approved Phase 3,Phase 2,Phase 1 57-83-0 5994
3
Paclitaxel Approved, Vet_approved Phase 2, Phase 3, Phase 1 33069-62-4 36314
4
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
5
Tamoxifen Approved Phase 3,Phase 2,Phase 1 10540-29-1 2733526
6
Carboplatin Approved Phase 2, Phase 3, Phase 1 41575-94-4 10339178 38904 498142
7
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
8
Goserelin Approved Phase 2, Phase 3 65807-02-5 5311128 47725
9
Trastuzumab Approved, Investigational Phase 2, Phase 3, Phase 1 180288-69-1 9903
10
Capecitabine Approved, Investigational Phase 2, Phase 3, Phase 1 154361-50-9 60953
11 Thiotepa Approved, Investigational Phase 3,Phase 2,Phase 1 52-24-4 5453
12
Lenograstim Approved, Investigational Phase 3,Phase 1,Phase 2 135968-09-1
13
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 216974-75-3
14
Epirubicin Approved Phase 3,Phase 2,Phase 1 56420-45-2 41867
15
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
16
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
17
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 1,Phase 2 50-02-2 5743
18
Cisplatin Approved Phase 3,Phase 2 15663-27-1 2767 441203 84093
19
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
20
Aprepitant Approved, Investigational Phase 3 170729-80-3 6918365 151165
21
Pertuzumab Approved Phase 3,Phase 1,Phase 2 380610-27-5, 145040-37-5 2540
22
Palonosetron Approved, Investigational Phase 3 135729-61-2, 135729-56-5, 119904-90-4 148211
23
Prochlorperazine Approved, Vet_approved Phase 3 1984-02-6, 58-38-8 4917
24
Fosaprepitant Approved Phase 3 172673-20-0 219090
25
Leuprolide Approved, Investigational Phase 2, Phase 3 53714-56-0 657181 3911
26
Letrozole Approved, Investigational Phase 2, Phase 3 112809-51-5 3902
27
leucovorin Approved, Nutraceutical Phase 3 58-05-9 143 6006
28
Citric Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 77-92-9 311
29
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
30
Docetaxel Approved May 1996, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124 9877265
31
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
32
Lapatinib Approved March 2007, Investigational Phase 2, Phase 3,Phase 1 231277-92-2, 388082-78-8 208908 9941095
33
Substance P Investigational Phase 3 33507-63-0 44359816
34 Progestins Phase 3,Phase 2
35 Alkylating Agents Phase 3,Phase 2,Phase 1
36 Selective Estrogen Receptor Modulators Phase 3,Phase 2,Phase 1
37 Folic Acid Antagonists Phase 3
38 Steroid Synthesis Inhibitors Phase 2, Phase 3
39 Albumin-Bound Paclitaxel Phase 2, Phase 3, Phase 1
40 Gastrointestinal Agents Phase 3,Early Phase 1
41 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
42 Nucleic Acid Synthesis Inhibitors Phase 3
43 Hormone Antagonists Phase 3,Phase 2,Phase 1
44 Dermatologic Agents Phase 3
45 Vitamin B Complex Phase 3
46 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1,Early Phase 1
47 Hormones Phase 3,Phase 2,Phase 1
48 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1,Early Phase 1
49 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1
50 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 105)

# Name Status NCT ID Phase Drugs
1 Standard Chemotherapy Compared With High-Dose Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Women With Advanced or Inflammatory Breast Cancer Unknown status NCT00003680 Phase 3 CMF regimen;cyclophosphamide;fluorouracil;methotrexate;tamoxifen citrate;thiotepa
2 Combination Chemotherapy in Treating Women With Breast Cancer Unknown status NCT00003679 Phase 3 cyclophosphamide;docetaxel;doxorubicin hydrochloride;tamoxifen citrate
3 Capecitabine and Paclitaxel (Albumin-Stabilized Nanoparticle Formulation) in Treating Women Undergoing Surgery for Stage II or Stage III Breast Cancer Unknown status NCT00397761 Phase 2, Phase 3 capecitabine;paclitaxel albumin-stabilized nanoparticle formulation
4 Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Nonmetastatic Breast Cancer Unknown status NCT01093235 Phase 3 cyclophosphamide;docetaxel;epirubicin hydrochloride;fluorouracil
5 Interest of Maintenance Chemotherapy After Induction Treatment for Inflammatory Breast Cancer Completed NCT02324088 Phase 3 Docetaxel;Cyclophosphamide;Epirubicin
6 Biomarker (p53 Gene) Analysis and Combination Chemotherapy Followed by Radiation Therapy and Surgery in Treating Women With Large Operable or Locally Advanced or Inflammatory Breast Cancer Completed NCT00017095 Phase 3 cyclophosphamide;docetaxel;epirubicin hydrochloride;fluorouracil
7 Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer Completed NCT01426880 Phase 2, Phase 3 Carboplatin;background treatment
8 A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto) Completed NCT02125344 Phase 3 non-pegylated liposomal doxorubicin;Carboplatin;Paclitaxel;Epirubicin;Cyclophosphamide;Pertuzumab;Trastuzumab;Ferric carboxymaltose
9 S0012 Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Filgrastim in Treating Women With Inflammatory or Locally Advanced Breast Cancer Completed NCT00016406 Phase 3 cyclophosphamide;doxorubicin;paclitaxel
10 Combination Chemotherapy With or Without Capecitabine and/or Trastuzumab Before Surgery in Treating Women With Stage I, Stage II, or Stage III Breast Cancer Completed NCT00288002 Phase 3 capecitabine;cyclophosphamide;docetaxel;epirubicin hydrochloride
11 Prevention of Delayed Nausea A Phase III Double-Blind Placebo-Controlled Clinical Trial Completed NCT00475085 Phase 3 aprepitant;dexamethasone;granisetron hydrochloride;palonosetron hydrochloride;prochlorperazine;placebo
12 Trial of Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response and Complete Response to Neoadjuvant Chemotherapy Recruiting NCT02879513 Phase 3 Paclitaxel;Cisplatin;Epirubicin;Cyclophosphamide;5-fluoruracil
13 Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients Recruiting NCT02221999 Phase 2, Phase 3 Paclitaxel;Cisplatin;Gonadotropin-releasing hormone agonist;Letrozole
14 Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto) Active, not recruiting NCT01583426 Phase 3 nab-Paclitaxel;Paclitaxel
15 Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer Terminated NCT00016276 Phase 3 dexrazoxane hydrochloride;doxorubicin hydrochloride;cyclophosphamide;paclitaxel;tamoxifen citrate
16 Breast-Conserving Therapy Compared With Mastectomy Followed By Radiation Therapy in Treating Women With Locally Advanced Breast Cancer Previously Treated With Chemotherapy Terminated NCT00028704 Phase 3
17 Docetaxel, Carboplatin, and Capecitabine as Treatment for Patients With Locally Advanced or Inflammatory Breast Cancer Before Surgery Unknown status NCT00251329 Phase 2 neoadjuvant chemotherapy
18 "Phase II Study of PET Guided Neoadjuvant Chemotherapy (NAC) and Oncotype Guided Hormonal Therapy of Breast Cancer" Unknown status NCT01641406 Phase 2 Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab;Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab;Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab
19 Addition of Paclitaxel to High-Dose Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer Unknown status NCT00002627 Phase 1, Phase 2 carboplatin;cyclophosphamide;mesna;paclitaxel
20 Docetaxel, Epirubicin, and Cyclophosphamide With or Without Trastuzumab in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery Unknown status NCT00398489 Phase 2 anastrozole;cyclophosphamide;docetaxel;epirubicin hydrochloride;goserelin acetate;tamoxifen citrate
21 Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer Completed NCT00558103 Phase 2 lapatinib;Pazopanib
22 Study Of Lapatinib In Patients With Relapsed Or Refractory Inflammatory Breast Cancer Completed NCT00105950 Phase 2 lapatinib
23 Epirubicin, Docetaxel, and Pegfilgrastim in Treating Women With Locally Advanced or Inflammatory Breast Cancer Completed NCT00066443 Phase 1, Phase 2 docetaxel;epirubicin hydrochloride
24 Bevacizumab to Treat Inflammatory Breast Cancer or Locally Advanced Breast Cancer Completed NCT00016549 Phase 2
25 Afatinib (BIBW2992) in HER2 (Human Epidermal Growth Factor Receptor 2)-Overexpressing Inflammatory Breast Cancer Completed NCT01325428 Phase 2 Afatinib once daily (OD);Vinorelbine Weekly
26 Weekly Gemcitabine, Epirubicin, and Docetaxel in Locally Advanced or Inflammatory Breast Cancer Completed NCT00193050 Phase 2 Gemcitabine;Epirubicin;Docetaxel
27 Study Of Lapatinib In Combination With Paclitaxel In The Treatment Of Newly Diagnosed Inflammatory Breast Cancer Completed NCT00111787 Phase 2 Lapatinib;Paclitaxel
28 Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer Completed NCT00193206 Phase 2 Gemcitabine;Epirubicin;Albumin-bound Paclitaxel
29 Addition of Cisplatin to Neoadjuvant Therapy for T Locally Advanced Breast Cancer Completed NCT02199418 Phase 2 Paclitaxel;Cisplatin
30 Neoadjuvant Pegylated Liposomal Doxorubicin and Cyclophosphamide +/- Trastuzumab Followed by Docetaxel in Breast Cancer Completed NCT01206881 Phase 2 pegylated liposomal doxorubicin
31 Tipifarnib, Doxorubicin, and Cyclophosphamide in Treating Women With Locally Advanced Breast Cancer Completed NCT00049114 Phase 2 doxorubicin hydrochloride;cyclophosphamide;tipifarnib
32 Neoadjuvant Tipifarnib, Docetaxel, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIA or Stage IIIB Breast Cancer Completed NCT00070252 Phase 1, Phase 2 Capecitabine;Docetaxel;Tipifarnib
33 A Multimodality Treatment Approach to Patients With Inflammatory Cancer of the Breast and Locally Advanced Non-Inflammatory Stage III Breast Cancer and Stage IV Breast Cancer Completed NCT00001193 Phase 2
34 NOV-002, Doxorubicin, Cyclophosphamide, and Docetaxel in Women With Newly Diagnosed Stage II or IIIC Breast Cancer Completed NCT00499122 Phase 2 Cyclophosphamide;Docetaxel;Doxorubicin;NOV 002
35 Doxorubicin and Docetaxel in Treating Women With Stage III Breast Cancer Completed NCT00005800 Phase 2 Docetaxel;Doxorubicin
36 Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer Completed NCT00003199 Phase 2 tamoxifen citrate;busulfan;thiotepa;melphalan
37 Liposomal Doxorubicin and Trastuzumab in Treating Women With Locally Advanced, Inflammatory, or Metastatic Breast Cancer Completed NCT00004925 Phase 1, Phase 2 pegylated liposomal doxorubicin hydrochloride
38 Phase I/II Study of Neoadjuvant Lapatinib in Breast Cancer Completed NCT00450892 Phase 1, Phase 2 docetaxel+lapatinib;docetaxel + trastuzumab;docetaxel + trastuzumab + lapatinib
39 Paclitaxel and Carboplatin in Treating Women Who Are Undergoing Surgery for Newly Diagnosed, Locally Advanced Breast Cancer Completed NCT00096343 Phase 2 carboplatin;paclitaxel
40 Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer Completed NCT00005798 Phase 2 Carboplatin;Cyclophosphamide;Thiotepa
41 Neoadjuvant or Adjuvant Epirubicin, Cyclophosphamide, and Paclitaxel in Treating Women With Stage I, Stage II, or Stage III Breast Cancer Completed NCT00072319 Phase 2 cyclophosphamide;epirubicin hydrochloride;paclitaxel
42 Multimodality Treatment for Women With Stage II, Stage III, or Stage IV Breast Cancer Completed NCT00006110 Phase 2 cyclophosphamide;doxorubicin hydrochloride;paclitaxel
43 S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer Completed NCT00856492 Phase 2 cyclophosphamide;doxorubicin hydrochloride;paclitaxel albumin-stabilized nanoparticle formulation
44 Trastuzumab and External Beam Radiation Therapy in Treating Women With Stage III or Stage IV Breast Cancer Completed NCT00943410 Phase 2 Herceptin
45 Xeloda (Capecitabine) and External Beam Radiation Completed NCT00916578 Phase 2 Capecitabine
46 Combination Chemotherapy With or Without Trastuzumab Followed By an Autologous Stem Cell Transplant and Radiation Therapy in Treating Patients With Stage III or Stage IV Breast Cancer Completed NCT00182793 Phase 2 carboplatin;cyclophosphamide;melphalan;thiotepa
47 Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer Completed NCT00464646 Phase 2 Epirubicin;Cyclophosphamide;Docetaxel;Trastuzumab;Bevacizumab
48 A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer Recruiting NCT02623972 Phase 2 Eribulin;Adriamycin;Cyclophosphamide
49 Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer Recruiting NCT02876302 Phase 2 Ruxolitinib;Paclitaxel;Doxorubicin;Cyclophosphamide
50 Study of Triple Combination of Atezolizumab + Cobimetinib + Eribulin (ACE) in Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer Recruiting NCT03202316 Phase 2 Cobimetinib;Atezolizumab;Eribulin

Search NIH Clinical Center for Inflammatory Breast Carcinoma

Cochrane evidence based reviews: inflammatory breast neoplasms

Genetic Tests for Inflammatory Breast Carcinoma

Anatomical Context for Inflammatory Breast Carcinoma

MalaCards organs/tissues related to Inflammatory Breast Carcinoma:

38
Breast, Skin, Prostate, Bone, Liver, Lymph Node, B Cells

Publications for Inflammatory Breast Carcinoma

Articles related to Inflammatory Breast Carcinoma:

(show top 50) (show all 101)
# Title Authors Year
1
Diffuse dermal angiomatosis mimicking inflammatory breast carcinoma. ( 28744985 )
2017
2
Gadolinium-Naive Nephrogenic Systemic Fibrosis of Breast Mimicking Inflammatory Breast Carcinoma. ( 28323787 )
2017
3
Bilateral breast filariasis mimicking inflammatory breast carcinoma. ( 29184008 )
2017
4
Cutaneous metastasis of inflammatory breast carcinoma mimicking an erythema annulare centrifugum: a sign of locally recurrent cancer. ( 27766674 )
2016
5
Idiopathic granulomatous mastitis mimicking inflammatory breast carcinoma: What are the odds? ( 27790396 )
2016
6
Confocal fluorescence microscopy for rapid evaluation of invasive tumor cellularity of inflammatory breast carcinoma core needle biopsies. ( 25417171 )
2015
7
Breast filariasis or inflammatory breast carcinoma? Reaching a diagnosis. ( 26567240 )
2015
8
Primary Neuroendocrine Carcinoma of the Breast with Clinical Features of Inflammatory Breast Carcinoma: A Case Report and Literature Review. ( 26770249 )
2015
9
Axillary high-grade B-cell non-Hodgkin lymphoma presenting under the guise of inflammatory breast carcinoma. ( 26670406 )
2015
10
Axillary lymph node tuberculosis masquerading as inflammatory breast carcinoma in an immune-compromised patient. ( 25681261 )
2015
11
Inflammatory Breast Carcinoma Presenting with Two Different Patterns of Cutaneous Metastases: Carcinoma Telangiectaticum and Carcinoma Erysipeloides. ( 26345728 )
2015
12
Response of an ERBB2-mutated inflammatory breast carcinoma to human epidermal growth factor receptor 2-targeted therapy. ( 24516025 )
2014
13
Comparison between invasive breast cancer with extensive peritumoral vascular invasion and inflammatory breast carcinoma: a clinicopathologic study of 161 cases. ( 25125618 )
2014
14
Collision tumor with inflammatory breast carcinoma and malignant phyllodes tumor: a case report and literature review. ( 24400686 )
2014
15
Antitumor Response of an ERBB2 Amplified Inflammatory Breast Carcinoma With EGFR Mutation to the EGFR-TKI Erlotinib. ( 24201163 )
2013
16
Inflammatory breast carcinoma. ( 23945485 )
2013
17
Unusual dermal pleomorphic calcifications in a case of inflammatory breast carcinoma. ( 24082417 )
2013
18
Inflammatory breast carcinoma. ( 23543972 )
2013
19
Status of the anaplastic lymphoma kinase (ALK) gene in inflammatory breast carcinoma. ( 24156086 )
2013
20
What can we learn from the age- and race/ethnicity- specific rates of inflammatory breast carcinoma? ( 21850396 )
2011
21
Gastric cancer in a pregnant woman presenting with low back pain and bilateral erythematous breast hypertrophy mimicking primary inflammatory breast carcinoma. ( 21378356 )
2011
22
A woman with multiple silicone rupture complicated by inflammatory breast carcinoma. ( 21443069 )
2011
23
p53 protein accumulation and presence of visceral metastasis are independent prognostic factors for survival in patients with metastatic inflammatory breast carcinoma. ( 21252573 )
2011
24
Inflammatory breast carcinoma and locally advanced breast carcinoma: characterisation with MR imaging. ( 20927653 )
2011
25
Metastatic prostatic adenocarcinoma mimicking inflammatory breast carcinoma: a case report. ( 20133250 )
2010
26
A case of inflammatory breast carcinoma: carcinoma erysipeloides. ( 20228568 )
2010
27
Is there a role for mammary stem cells in inflammatory breast carcinoma?: a review of evidence from cell line, animal model, and human tissue sample experiments. ( 20503411 )
2010
28
Image of the month. Inflammatory breast carcinoma. ( 20157092 )
2010
29
Intravascular ALK-positive anaplastic large-cell lymphoma mimicking inflammatory breast carcinoma. ( 19364961 )
2009
30
Triple negative phenotype and N-ratio are important for prognosis in patients with stage IIIB non-inflammatory breast carcinoma. ( 19798691 )
2009
31
Fallopian tube cancer presenting as inflammatory breast carcinoma: report of a case and review of the literature. ( 19899419 )
2009
32
Secondary involvement of the breast in T-cell non-Hodgkin lymphoma, an unusual example mimicking inflammatory breast carcinoma. ( 19082616 )
2009
33
Inflammatory breast carcinoma as a model of accelerated self-metastatic expansion by intravascular growth. ( 19707200 )
2009
34
Pathologic aspects of inflammatory breast carcinoma: part 1. Histomorphology and differential diagnosis. ( 18308143 )
2008
35
Inflammatory breast carcinoma in magnetic resonance imaging: a comparison with locally advanced breast cancer. ( 18206620 )
2008
36
Magnetic resonance imaging of inflammatory breast carcinoma and acute mastitis. A comparative study. ( 18523781 )
2008
37
c-Met overexpression in inflammatory breast carcinomas: automated quantification on tissue microarrays. ( 17242702 )
2007
38
Nephrogenic systemic fibrosis mimicking inflammatory breast carcinoma. ( 17227116 )
2007
39
Metastatic esophageal carcinoma masquerading as inflammatory breast carcinoma. ( 17343591 )
2007
40
[Biological significance of E-cadherin in an inflammatory breast carcinoma cell line]. ( 16737610 )
2006
41
Docetaxel administered during pregnancy for inflammatory breast carcinoma. ( 16595038 )
2006
42
Disease-free and overall survival after pathologic complete disease remission of cytologically proven inflammatory breast carcinoma axillary lymph node metastases after primary systemic chemotherapy. ( 16444747 )
2006
43
Unique features of inflammatory breast carcinoma. ( 16094760 )
2005
44
Tumor lymphangiogenesis in inflammatory breast carcinoma: a histomorphometric study. ( 16278382 )
2005
45
Imaging in inflammatory breast carcinoma. ( 16735786 )
2005
46
Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute. ( 15998949 )
2005
47
Inflammatory breast carcinoma: the sphinx of breast cancer research. ( 14722054 )
2004
48
Do younger women with non-metastatic and non-inflammatory breast carcinoma have poor prognosis? ( 14736343 )
2004
49
Inflammatory breast carcinoma: outcomes with trimodality therapy for nonmetastatic disease. ( 14983486 )
2004
50
Long-term results of combined-modality therapy for inflammatory breast carcinoma. ( 15585073 )
2004

Variations for Inflammatory Breast Carcinoma

Expression for Inflammatory Breast Carcinoma

Search GEO for disease gene expression data for Inflammatory Breast Carcinoma.

Pathways for Inflammatory Breast Carcinoma

Pathways related to Inflammatory Breast Carcinoma according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
1 12.46 CDH1 EGFR ERBB2 ESR1
2
Show member pathways
12.22 CDH1 EGFR ERBB2 ESR1 PGR
3
Show member pathways
12.19 CDH1 EGFR ERBB2
4
Show member pathways
12 EGFR ERBB2 ESR1
5 11.96 EGFR ERBB2 ESR1
6 11.77 CDH1 EGFR ESR1
7
Show member pathways
11.51 EGFR ERBB2 ESR1
8 11.36 CDH1 EGFR ERBB2
9 11.29 CDH1 EGFR ERBB2
10 11.24 EGFR ESR1
11 11.2 EGFR ERBB2
12 11.14 CDH1 EGFR
13 10.99 EGFR ERBB2
14
Show member pathways
10.96 EGFR ERBB2 ESR1 PGR
15 10.74 CDH1 EGFR
16 10.62 CDH1 EGFR ERBB2

GO Terms for Inflammatory Breast Carcinoma

Biological processes related to Inflammatory Breast Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signal transduction by protein phosphorylation GO:0023014 9.46 EGFR ERBB2
2 positive regulation of fibroblast proliferation GO:0048146 9.43 EGFR ESR1
3 cellular response to epidermal growth factor stimulus GO:0071364 9.4 EGFR ERBB2
4 ERBB2 signaling pathway GO:0038128 9.37 EGFR ERBB2
5 cellular response to estradiol stimulus GO:0071392 9.32 EGFR ESR1
6 regulation of cell motility GO:2000145 9.26 EGFR ERBB2
7 positive regulation of transcription, DNA-templated GO:0045893 9.26 CDH1 EGFR ESR1 PROX1
8 regulation of ERK1 and ERK2 cascade GO:0070372 9.16 EGFR ERBB2
9 negative regulation of ERBB signaling pathway GO:1901185 8.62 EGFR ERBB2

Molecular functions related to Inflammatory Breast Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.55 CDH1 EGFR ERBB2 ESR1 PGR
2 core promoter sequence-specific DNA binding GO:0001046 9.37 ESR1 PROX1
3 nuclear receptor activity GO:0004879 9.32 ESR1 PGR
4 steroid binding GO:0005496 9.26 ESR1 PGR
5 signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 8.96 EGFR ERBB2
6 nitric-oxide synthase regulator activity GO:0030235 8.62 EGFR ESR1

Sources for Inflammatory Breast Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....